Greatbatch Sets Up Shop In Singapore: Targets Emerging Markets
In July, Greatbatch Inc. announced that its QiG Group established a research and development center in Singapore, with a focus on the development of active implantable medical devices, that is, the kinds of devices that are powered by batteries or other sources. Greatbatch thus sets up a regional presence that will help it develop medical devices that address the specific needs of emerging markets in the Asia-Pacific region. The Singapore initiative is also a stake in the ground for Greatbatch’s strategy to remake itself and the medical device industry.
You may also be interested in...
China has shown willingness to go tit-for-tat in its bilateral disputes with the US and the latest comments from US officials show an underlying distrust over clinical data and vaccines safety in China, raising fresh concerns just when collaboration is needed to accelerate availability of the first vaccines in the global pandemic.
Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA vaccine. Also, Evidence Accelerator's next joint parallel analysis projects are remdesivir in hospitalized patients and coagulopathy.
House Democrats criticized the administration’s response to the pandemic in a new report. See what Rep. James Clyburn, chairman of the Select Subcommittee on the Coronavirus Crisis, said about it here.